Theranostics, An Issue of PET Clinics

1st Edition, Volume 16-3 - June 7, 2021
Editors: Ali Gholamrezanezhad, Hojjat Ahmadzadehfar
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 8 1 3 0 7 - 5
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 8 1 3 0 8 - 2

This issue of PET Clinics focuses on Theranostics and is edited by Drs. Ali Gholamrezanezhad and Hojjat Ahmadzadehfar. Articles will include: Good Clinical Practice for… Read more

Purchase options

Info / Buy

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

This issue of PET Clinics focuses on Theranostics and is edited by Drs. Ali Gholamrezanezhad and Hojjat Ahmadzadehfar. Articles will include: Good Clinical Practice for Theranostics; Theranostics in Neuroendocrine Tumors; Neuroendocrine Tumors: Imaging Perspective; Prostate Cancer Theranostics: From Target Description to Imaging; Prostate Cancer Theranostics: PSMA-targeted Therapy; Theranostics in Brain Tumors; Theranostics in Neuroblastoma; Theranostics in Thyroid Cancer; and more!

Cover image
Title page
Table of Contents
Copyright
Contributors
Forthcoming Issues
CME Accreditation Page
General Concepts in Theranostics
Key points
Introduction
Discussion
Controversies
Perspectives
Summary
Clinics care points
An Impressive Approach in Nuclear Medicine: Theranostics
Key points
Introduction
Treatment of hyperparathyroidism and thyroid cancer in nuclear medicine
Treatment of neuroendocrine tumor in nuclear medicine
Treatment of prostate cancer in nuclear medicine
Treatment of bone metastases in nuclear medicine
Theranostics applications in neuroblastoma
Treatment of melanoma in nuclear medicine
Theranostics applications in multiple myeloma
A new horizon for tumor targeting and therapy: fibroblast activation protein inhibitor
Summary
The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging
Key points
Introduction
Tumor stroma
Fibroblast activation protein ligands in PET imaging
Summary
Clinics care points
Neuroendocrine Tumors: Imaging Perspective
Key points
Introduction
Role of PET imaging to identify patients with somatostatin receptor positivity
joint 18F-fluorodeoxyglucose and 68Ga-DOTA-peptide PET/computed tomography use in the evaluation of neuroendocrine tumor
Outstanding questions in imaging of neuroendocrine tumors for peptide radionuclide receptor therapy planning
Imaging to quantify dose
Can dose absorbed be predicted based on functional imaging?
The principles of individualized dosimetry
Variability and standardization of individualized dosimetry
Ensuring consistency of dose estimates across centers through quality assurance
From absorbed dose to biological effective dose
Imaging to predict outcomes
Summary
Disclosures
Clinics care points
Theragnostics in Neuroendocrine Tumors
Key points
Introduction
Clinical care points
Discussion
Summary
Theranostics in Thyroid Cancer
Key points
Introduction
Sodium-iodine symporter
Radioiodine therapy in differentiated thyroid cancer
Radioiodine imaging with 131I
Radioiodine-refractory differentiated thyroid cancer
Redifferentiation therapy
Further possibilities of theranostics in thyroid cancer
Summary
Clinics care points
Prostate Cancer Theranostics: From Target Description to Imaging
Key points
Introduction
Prostate-specific membrane antigen
Prostate-specific membrane antigen-based imaging and theranostics
Factors influencing prostate-specific membrane antigen expression
The prostate-specific membrane antigen radioligands
Theranostic imaging
Controversies in PSMA imaging
Summary
Clinics care points
Prostate Cancer Theranostics: PSMA Targeted Therapy
Key points
Introduction
Imaging and therapy
Future directions
Disclosures
Theranostics in Brain Tumors
Key points
Introduction
Biological targets for targeted therapy
Routes of drug delivery to brain tumors
PET-based precision imaging and current challenges of theranostics in neuro-oncology
Target expression assessment and tumor heterogeneity
Pharmacokinetic assessment and biodistribution
Evaluation of pharmacodynamics and cancer biology monitoring
Future directions
Summary
Conflict of interest
Financial disclosures
Clinics care points
Theranostics in Neuroblastoma
Key points
Introduction
Discussion
Summary
Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders
Key points
Introduction
Theranostic approaches in the management of infections
Theranostic approaches for cardiovascular diseases
Theranostics approaches for rheumatic disease
Future directions
Summary
Clinics care points
Theranostic Agents in Musculoskeletal Disorders
Key points
Rheumatoid arthritis
Osteoarthrosis
Multiple myeloma
Sarcoma
Clinics care points